Kano Model
for Manufacture of pharmaceuticals, medicinal chemical and botanical products (ISIC 2100)
The Kano Model has a very high industry fit for pharmaceuticals due to the high-stakes nature of R&D investments (IN05), the imperative for market differentiation, and the complex interplay of stakeholder needs (patients, HCPs, payers). Its 'primary' relevance and Priority 5 rating, coupled with...
Strategic Overview
The Kano Model is a powerful framework for prioritizing product features based on customer satisfaction, which is highly relevant for the pharmaceutical industry. It classifies features into 'basic' (must-haves, e.g., safety, efficacy), 'performance' (more is better, e.g., faster onset, improved tolerability), and 'delighters' (unexpected, innovative features, e.g., novel delivery systems, comprehensive patient support). In an industry characterized by exorbitant R&D costs (IN05) and lengthy development timelines, efficiently allocating resources to features that genuinely create stakeholder value is paramount.
This model enables pharmaceutical companies to differentiate products in crowded markets and optimize market access by identifying what truly drives satisfaction and value beyond core efficacy. It's crucial for making strategic R&D investment decisions, ensuring that resources are directed towards features that will maximize uptake, adherence, and commercial success, rather than merely meeting basic regulatory requirements. The model helps navigate market access challenges (CS01), balance innovation with affordability (MD03), and ensures R&D yields products that are not just effective but also highly desirable and commercially successful.
By systematically categorizing features from the perspective of patients, prescribers, and payers, the Kano Model mitigates the risk of 'Rapid Obsolescence and Competitive Pressure' (IN01) by ensuring product features are precisely aligned with unmet or under-satisfied needs. It also informs compelling value propositions for payers, demonstrating how specific product attributes translate into better outcomes and cost-effectiveness, thereby justifying pricing and securing reimbursement.
5 strategic insights for this industry
Safety, Efficacy, and Regulatory Approval are Non-Negotiable Basic Requirements
For any pharmaceutical product, proven safety, efficacy, and subsequent regulatory approval (e.g., FDA, EMA) are absolute 'basic' attributes. Without these foundational elements, no other feature, however innovative, will lead to market acceptance or commercial viability. These are the entry tickets to the market.
Performance Attributes Drive Competitive Preference and Adherence
Features such as improved tolerability (fewer side effects), convenient dosing regimens (e.g., once daily), faster onset of action, or reduced drug-drug interactions often fall into the 'performance' category. These attributes significantly influence physician prescribing preferences and patient adherence, creating a competitive advantage in a crowded market.
Beyond-the-Pill Solutions Act as Key 'Delighters'
True 'delighters' in pharma often extend beyond the molecule itself, encompassing comprehensive patient support programs, integrated digital health tools for disease management (e.g., remote monitoring, personalized apps), or novel, patient-friendly administration methods (e.g., smart auto-injectors). These innovations differentiate a drug, enhance the patient experience, and can justify premium pricing.
Payer Value Drivers Often Include Cost-Effectiveness and Real-World Outcomes
From a payer's perspective, cost-effectiveness, budget impact, and demonstrable real-world outcomes often function as 'performance' or even 'basic' requirements for reimbursement and formulary inclusion. 'Delighters' for payers might include risk-sharing agreements, data integration capabilities, or evidence of significant healthcare resource utilization reduction.
Feature Classification Evolves Over Product Lifecycle and Market Maturity
What begins as a 'delighter' (e.g., a breakthrough mechanism of action, a once-daily formulation) can quickly become a 'performance' attribute and eventually a 'basic' expectation as competitors introduce similar or superior features. Regular re-evaluation of Kano classifications is essential for maintaining competitive relevance and maximizing revenue post-patent expiry.
Prioritized actions for this industry
Conduct Multi-Stakeholder Kano Surveys for Pipeline and In-Market Products
Systematically survey patients, HCPs (physicians, nurses, pharmacists), and payers to classify existing and potential drug/service features. This identifies the most impactful areas for R&D investment, market differentiation, and value proposition development, addressing 'High R&D Investment for New Products' (MD01) and 'Market Access Barriers & Adoption Challenges' (CS01).
Prioritize R&D Portfolio Allocation Based on Kano-Derived Insights
Allocate R&D budget towards developing 'performance' and 'delighter' features that offer significant competitive advantage and address unmet needs, while ensuring 'basic' requirements are unequivocally met. This maximizes ROI on high R&D investments (IN05) and mitigates 'High R&D Investment Risk' (MD01) by focusing on value-generating attributes.
Develop 'Beyond-the-Pill' Delighter Strategies and Integrated Solutions
Invest in comprehensive patient support programs, digital therapeutics, integrated diagnostics, or novel drug delivery systems that enhance the patient experience and clinical outcomes. This creates strong brand loyalty, improves patient adherence, and supports premium pricing, addressing 'Balancing Innovation with Affordability' (MD03) and 'Market Access Barriers & Adoption Challenges' (CS01).
Regularly Re-evaluate Feature Categorization Throughout the Product Lifecycle
Re-assess Kano classifications for products nearing patent expiry, facing new competition, or as market expectations evolve. This adaptive approach ensures product strategies remain relevant and competitive, allowing for timely innovation or strategic divestment, addressing 'Maintaining Revenue Growth Post-Patent Expiry' (MD01) and 'Rapid Obsolescence and Competitive Pressure' (IN01).
Integrate Kano Insights into Value Dossier Development and Payer Communications
Frame drug features and their benefits in market access submissions and communications to payers according to their Kano classification. Clearly articulate how 'performance' and 'delighter' features translate into superior value, cost-effectiveness, or improved real-world outcomes to justify pricing and secure favorable reimbursement terms, addressing 'Increasing Payer Scrutiny and Price Pressure' (MD03) and 'Navigating Payer & Reimbursement Landscape' (IN04).
From quick wins to long-term transformation
- Conduct an internal workshop with product, R&D, and commercial teams to qualitatively categorize existing drug features (basic, performance, delighter) for a flagship product and a key pipeline asset.
- Run a small, focused Kano survey with a limited number of Key Opinion Leaders (KOLs) or patient advocacy group members to validate internal assumptions for a new pipeline asset.
- Identify one potential 'delighter' feature (e.g., improved patient education materials or a simple digital reminder tool) for a current product and pilot its introduction.
- Integrate quantitative Kano surveys into market research protocols for all late-stage pipeline products and key in-market assets, covering patients, HCPs, and payers.
- Establish a cross-functional 'Value Features' team (R&D, Marketing, Market Access, Medical Affairs) to align on feature prioritization and strategic development based on Kano insights.
- Develop a strategic roadmap for 'beyond-the-pill' services based on identified delighter opportunities, outlining technology requirements and regulatory pathways.
- Embed Kano methodology as a core component of the entire product lifecycle management process, from early discovery and development to post-market surveillance and strategic updates.
- Continuously monitor the competitive landscape and evolving stakeholder expectations to proactively shift feature focus and anticipate future 'basic' requirements or 'delighter' opportunities.
- Build internal capabilities for developing, integrating, and validating digital health solutions and personalized medicine approaches as core 'delighters' that differentiate products and improve patient outcomes.
- Applying Kano only to patients, neglecting the equally critical perspectives of HCPs, payers, and regulators.
- Misinterpreting stakeholder needs or assuming 'delighters' without rigorous qualitative and quantitative validation.
- Over-investing in 'delighters' before 'basic' and 'performance' needs are fully met and secured (e.g., robust efficacy and safety profile).
- Failing to adapt Kano classifications as the market matures, competitive offerings emerge, or patient/HCP expectations shift.
- Underestimating regulatory hurdles and compliance requirements for 'beyond-the-pill' services and digital health solutions (e.g., medical device regulations, data privacy).
Measuring strategic progress
| Metric | Description | Target Benchmark |
|---|---|---|
| New Product Feature Adoption Rate | Percentage of target HCPs prescribing or patients adopting newly introduced 'performance' or 'delighter' features (e.g., patient app downloads, use of specific device). | >60% within 1 year of launch for key features |
| Physician Preference Scores for Differentiated Features | HCP preference for the company's drug over competitors, specifically attributed to identified 'performance' or 'delighter' features in market research surveys. | Top 2 preference for X% of HCPs in targeted specialty |
| Patient Adherence & Satisfaction Scores (Linked to Features) | Measured via patient reported outcomes or direct surveys, specifically linking improved adherence and satisfaction to the presence or quality of 'performance' or 'delighter' features. | Improvement in adherence by X% and satisfaction scores by Y% for users of these features |
| Market Share Growth Attributable to Differentiated Features | Percentage increase in market share for a product, with growth specifically linked to the introduction or clear communication of identified 'performance' or 'delighter' features. | X% market share increase/maintenance in competitive markets |
| Reimbursement Success Rate & Formulary Positioning | Percentage of positive formulary decisions and preferred positioning for new drugs, directly correlated with the perceived value and utility of 'performance' and 'delighter' features by payers. | >70% positive formulary decisions with favorable access tiers |
Other strategy analyses for Manufacture of pharmaceuticals, medicinal chemical and botanical products
Also see: Kano Model Framework